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ABSTRACT:  
The objective of present research work was formulation and development fast dissolving film of domperidone. Domperidone is a specific blocker of dopamine 
receptors Solvent casting method was used for preparation of fast dissolving film. Various film forming polymers were evaluated for selection of suitable 
polymer. Different polymers like maltodextrin, polyvinyl alcohol and different grades of hydroxypropyl methylcellulose like HPMC E5 LV, HPMC E15 LV 
and HPMC E3 LV were used in study for selection of polymers. Amongst them HPMC E3 LV, HPMC E5 LV was selected as film forming polymer and 
propylene glycol was used as plasticizer. For solubility enhancement inclusion complex from β-cyclodextine was prepared by kneading method. Films were 
evaluated for physical and mechanical properties, drug content, disintegration time, in vitro dissolution and stability study. Prepared films showed satisfactory 
physical  and  mechanical  properties.  Drug-excepients  interaction  study  (IR  spectroscopy),  Differential  scanning  calorimetry  (DSC),  Drug  content, 
disintegration time and in vitro dissolution were also acceptable. 3
2 factorial design were used for optimization of film formulation. Batch F4 was found to be 
optimized film formulation which has 35.33 second disintegration time, tensile strength 2.180 N/cm
2, drug release 75.26% after 15 min.  Acelerated stability 
studies on the promising formulations indicated that there were no significant changes in drug content, in vitro disintegration time, tensile strength, in vitro 
dissolution and surface pH.  
Keywords: Domperidone, Fast dissolving film, β-cyclodextine, Solvent casting method, 3
2 Factorial design. 
 
INTRODUCTION 
Among the various routes, Oral route is most preferred for 
drug administration. Most of the drugs are being taken in the 
form of tablets and capsules by all patients, including adult, 
pediatric and geriatric patients. As a site for drug delivery, 
oral  cavity  offers  advantages  over  the  conventional 
gastrointestinal route  and  the  parenteral  and  other  mucosal 
routes of drug administration. It provides direct entry into the 
systemic  circulation thereby avoiding the hepatic first pass 
effect,  ease  of  administration.  Intraoral  drug  delivery  has 
become an important route of drug administration. Various 
intraoral dosage forms have been developed, which includes 
adhesive  tablets,  gels,  ointments,  patches,  fast-dissolving 
drug  delivery  systems  (FDDDS).  FDDDS  is  the  most 
convenient  mode  of  administering  drugs  to  overcome 
problems  related  to  swallowing  difficulties.  These  delivery 
systems dissolve or disintegrate in the mouth rapidly, without 
requiring any water to aid in swallowing. Dissolution within 
oral cavity also permits intra-oral absorption, thus bypassing 
first-pass effects.
1 
A  fast-dissolving  film  drug  delivery  system  in  this  a  film 
containing active ingredient that dissolves or disintegrates in 
the saliva remarkably fast, within a few seconds without the 
need  for  water  or  chewing.  Some  drugs  are absorbed  well 
from  the  mouth,  pharynx  and  esophagus.  In  such  cases, 
bioavailability  of  drug  is  significantly  greater  than  those 
observed from conventional tablet dosage  form. Most fast-
dissolving delivery system films must include substances to 
mask the taste of the active ingredient. This masked active 
ingredient  is  then  swallowed  by  the  patient's  saliva  along 
with the soluble and insoluble excipients
.2  
Domperidone facilitates gastric emptying and decreases small 
bowel  transit  time  by  increasing  esophageal  and  gastric 
peristalsis  and  by  lowering  esophageal  sphincter  pressure. 
The antiemetic properties of domperidone are related to its 
dopamine  receptor  blocking  activity  at  both  the 
chemoreceptor  trigger zone  and  at the  gastric  level.  It has 
strong  affinities  for  the  D2  and  D3  dopamine  receptors, 
which are found in the chemoreceptor trigger zone, located 
just outside the blood brain barrier, which - among others - 
regulates nausea and vomiting. 
The objectives of the present work were preparation of fast 
dissolving  films  of  domperidone  using  water  soluble 
polymers having acceptable mechanical properties and faster 
dissolution, to achieve faster onset of action, to increase the 
bioavailability of Domperidone, to improve compliances & 
ease  of  dosing  for  the  patients  and  bypass  the  first  pass 
metabolism. 
MATERIALS AND METHODS 
Domperidone was obtained as gift sample from Esquire Drug 
House  (Surendranagar,  India). 
Hydroxypropylmethylcellulose  (HPMC  E3,  HPMC  E5, 
HPMC  E15)  were  procured  from  Colorcon  Pvt.  Ltd, 
Mumbai. Polyvinyl Alcohol (PVA), β-cyclodextrine (β-CD), 
Xanthan  gum  were  procured  from  SD  Fine  Chem  Ltd, 
Mumbai, India. Glycerol IP was obtained from RFCL Ltd, 
New Delhi. All other reagents used were of analytical grade. 
The inclusion complexes were prepared by kneading method 
and films were prepared by solvent casting method. 
Phase solubility studies 
Phase  solubility  studies  were  performed  according  to  the 
method reported by Higuchi and Connors. An excess amount 
of  Domperidone  (10  mg)  was  added  to  10  ml  of  distilled 
water containing rising amounts of β-CD solutions at various 
concentrations (0.001-0.01 M) in 10 ml volumetric flask. The 
contents  were  stirred  at  37°C  for  72  h  on  a  rotary  flask 
shaker. After equilibrium, the samples were filtered through 
whatman filter paper and absorbances were recorded at 283 
nm using UV visible spectrophotometer, if necessary, after 
suitable  dilution.  The  apparent  stability  constant  was 
calculated  from  the  initial  straight  portion  of  the  phase 
solubility diagram using the following equation:  
 
Where,  S  =  solubility  of  drug  without  cyclodextrine;  M = 
molar concentration; K = apparent stability constant; Slope is 
calculated from regression equation. 
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Preparation of inclusion complexes 
Domperidone inclusion complexes were prepared with β-CD 
in  different  ratio  (1:0.5,  1:1,  1:1.5  and  1:2)  by  kneading 
method.  Domperidone  and  β-CD  were  weighed  and 
transferred to mortar and kneaded for 45 min using alcohol-
water mixture in ratio 1:1, sufficient solvent was added to 
maintain paste like consistency. The resulting paste was then 
dried in the oven at 50° for 24 h. The dried complexes were 
ground  in  a  mortar  for  2  min  and  passed  through  sieve 
No.100. The prepared complexes were stored in glass vials 
and used for further studies. 
Dose calculation for Domperidone 
The dose to be incorporated in a patch was calculated in film 
was calculated using the following mathematical equation: 
 
Where, Css is concentration at steady state (20.7 µg L
-1), Ke is 
elimination rate constant (0.7545 h
-1). Vd  is volume of 
distribution (440 L).
3 
The dose of Domperidone is 7 mg/4 cm
2. Amount of drug 
present  in  70.84  cm
2  of  petridish  was  123.97  mg  for  all 
formulations.
3,4 
Preparation of fast dissolving films 
Fast-dissolving  film  of  domperidone  was  prepared  by  the 
solvent-casting  method.  From  the  preliminary  physical 
observation of the films prepared the best compositions were 
selected  for  the  incorporation  of  domperidone.  Aqueous 
solution  was  prepared  by  dissolving the  polymer  in  15  ml 
distilled water and was allowed to stirr for 4 h and kept for 1 
h  to  remove  all  the  air  bubbles  entrapped.  The  drug  and 
plasticizer were dissolved in smaller amounts of ethanol. This 
mixture was then added to the aqueous viscous solution and 
stirred for 1 h.  The entrapped air was removed by vacuum. 
Then the mixture solution was casted as a film onto a plastic 
petridish and dried in the oven at 50°C for 24 h. The film was 
carefully  removed  from  the  petridish,  checked  for  any 
imperfections, and cut into the 2 cm×2 cm in size, in which 7 
mg  domperidone  was  present.  The  films  were  stored  in  a 
glass container maintained at a temperature of 30°±1°C and 
relative humidity 60±5% until further analysis.
5,6,7 
Experimental design 
A 3
2 full factorial design was employed to study the effect of 
independent variables such as HPMC E3 (X1) and HPMC E5 
(X2) on the dependent variables like Tensile strength (N/cm
2), 
Disintegration  time  (sec)  and  percentage  of  drug  dissolved 
(%). In this design, two factors were evaluated, each at three 
levels and experimental batches were performed at all nine 
possible  combinations.  The  data  were  subjected  to  contour 
and 3-D response surface plot in Design-Expert® 8.0.7.1 (a 
software developed by Stat-Ease) to determine the effect of 
polymers on the release of drug and the dependent variables. 
The values of variables in 3
2 factorial designs are indicated in 
Table  1.    A  statistical  model  incorporating  interactive  and 
polynomial  terms  was  used  to  calculate  the  responses  as 
follows: 
 
Where, Y is the dependent, b0 is the arithmetic mean response 
of the all trials, and bi (b1, b2, b12, b11 and b22) is the estimated 
coefficient for the corresponding factor Xi ( X1, X2, X1X2, X11 
and X22) which represents the average result of changing one 
factor at a time from its low to high value. The interaction 
term  (X1  X2)  shows  how  the  response  changes  when  two 
factors  are  simultaneously  changed.  The  polynomial  terms 
(X1X1 and X2X2) are included to investigate the nonlinearity. 
The composition of the factorial design batches F1 to F9 are 
shown  in  Table  1  and  Table  2.  Each  formulation  was 
contained  1%W/V  of  PVA,  0.35%W/V  of  mannitol, 
0.15%W/V  of  xanthan  gum,  1.3  ml  of  PG  and  0.3  ml  of 
glycerol.
8 
Thickness Measurement 
The  thickness  of  the  Fast  dissolving  film  (2×2  cm
2)  was 
determined by using a screw gauge. The thickness of each 
film  at  three  different  places  determined  and  standard 
deviation was also calculated.
9,10 
Drug content uniformity 
Fast dissolving film of size 4 cm
2 was cut into small pieces 
and  transferred  into  a  graduated  glass  stoppered  flask 
containing  about  10  ml  of  6.8  pH  phosphate  buffers.  The 
flask  was  charge  on  rotary  flask  shaker  for  24  hrs.  The 
solution  was  filter  and  the  amount  of  drug  present  is 
determined by UV spectrophotometric method.
11,12 
Weight variation 
Three individual batches of fast dissolving film of size (2×2 
cm
2) was weighed on an electronic balance and the average 
weight and standard deviation was calculated.
13 
Surface pH 
The  surface  pH  of  fast  dissolving  film  was  determined  in 
order to investigate the possibility of any side effect in vivo. 
As an acidic or alkaline pH may cause irritation of the oral 
mucosa, it was determined to keep the surface pH as close to 
neutral as possible. A combined pH electrode was used for 
this  purpose.  Oral  film  was  slightly  wet  with  the  help  of 
water. The  pH  was  measured  by  bringing  the  electrode  in 
contact with the surface of the oral film.  The procedure was 
performed in triplicate and average with standard deviation 
was reported.
14 
Tensile strength 
Mechanical properties of the polymeric fast dissolving film 
were  conveniently  determined  by  measuring  their  tensile 
strength. The tensile strength of the fast dissolving film was 
determined  using  handmade  tensile  strength  instrument. 
Average reading of three fast dissolving films was taken as 
the tensile strength. The fast dissolving film was fixed to the 
assembly, the weights required to break the film was noted.
15-
18  Tensile  strength  was  calculated  using  the  following 
formula, 
 
Where, L = elongated length of the film.
 
Percentage elongation 
Percent elongation was mainly based on tensile strength of 
films. The nature of polymers affects tensile strength and % 
elongation.  Percentage  elongation  was  calculated  by 
measuring  the  increase  in  length  of  the  film  after  tensile 
strength measurement using the following formula.
9,19  
 
Where, LF = final length, LO= initial length. 
Folding endurance 
Folding endurance measures the ability of patch to withstand 
rupture, higher the folding endurance lower was chances of 
film  to  rupture  easily  and  vice  versa.  This  parameter  was 
determined by repeatedly folding one film at the same place 
till it broke. The number of times the film could be folded at 
the same place without breaking/cracking give the value of 
folding endurance.
20,21,22 
% Moisture content 
This test was also carried to evaluate the integrity of films at 
dry condition. Film of 4 cm
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accurately  and  kept  in  a  desiccator  containing  fused 
anhydrous calcium chloride. After 24 h the film was removed 
and  weighed.  Percentage  moisture  content  of  film  was 
determined as follows. 
 
 
In vitro Disintegration Time 
The  disintegration  time  is  the  time  when  a  film  breaks  or 
disintegrates. The test was performed using the same method 
as mentioned by setouhy et al. with slight modification. The 
film size required for dose delivery (2×2 cm) was placed on 
glass petri dish containing 10 ml of 6.8 phosphate buffer. The 
time  required  for  breaking  of  film  was  noted  as  in  vitro 
disintegration time.
7,11 
In vitro Dissolution Time 
Cumulative  drug  release  and  cumulative  %  drug  retained 
were calculated on the basis of drug content of domperidone 
present in the respective  film. The in vitro dissolution test 
was  performed  using  the  USP  basket  type  apparatus.  The 
dissolution studies were carried out at 37±0.5°C; with stirring 
speed of 100 rpm in 400 ml phosphate buffer pH 6.8 with 
20% v/v propylene glycol. The film size required for dose 
delivery  (2×2  cm)  was  used.  Five  milliliters  aliquots  of 
dissolution  media  were  collected  at  predetermined  time 
intervals of 2, 4, 6, 8, and 10 min and replaced with equal 
volumes  of  distilled  water.  The  collected  samples  were 
filtered  through  0.45  µm  membrane  filter  and  the 
concentration of the dissolved domperidone was determined 
at  appropriate  wavelength  using  the  UV-Visible 
spectrophotometer.
11,23,24 
In vitro permeation studies 
In  vitro  permeation  studies  through  cellophane  membrane 
was  carried  out  using  the  Franz  diffusion  cell  of  internal 
diameter of 2.5 cm. The cellophane membrane was mounted 
between the donor and receptor compartments. The receptor 
compartment was filled with 15 ml of phosphate buffer of pH 
7.4 with 20% v/v PEG which was maintained at 37± 0.2
oC 
and hydrodynamics were maintained using magnetic stirrer. 
One  film  of  dimension  2  cm  ×  2  cm  was  previously 
moistened with a few drops of pH 6.8 phosphate buffer and 
placed in donor compartment. The donor compartment was 
filled with 1 ml of pH 6.8 phosphate buffer. 1 ml samples 
from receptor compartment were withdrawn at suitable time 
interval  which  was  then  replaced  with  1  ml  of  pH  7.4 
phosphate buffer. The percentage of domperidone permeated 
was determined by measuring the absorbance in UV
spectrophotometer at λmax of 283 nm.
14,17,18 
Viscosity measurement 
Viscosity of the samples was determined using a Brookfield 
digital viscometer (Model no: Brookfield LV.DV-III ULTRA 
Programmable  Rheometer)  with  spindle  S62.The  sample 
temperature  was  controlled  at  25±1ºC  before  the  each 
measurements.  The  optimized  formulation  viscocity  by 
dissolving film in 3 ml 6.8 phosphate buffer.
16  
Stability studies 
The optimized formulation was subjected to stability studies 
as  per  International  Conference  on  Harmonization  (ICH 
guidelines) the sample was packed in an aluminum foil. Then 
stored  stability  chamber  controlled  at  accelerated  testing 
condition at 40
0C / 75 % RH for 3 months
 and evaluated for 
their  physical  appearance,  drug  content,  in  vitro 
disintegration time, drug release at
 1 month intervals of time 
and results were reported.
25,26 
Pharmacokinetic study of prepared fast dissolving films 
Data obtained from dissolution studies were fitted to various 
kinetic equations. The kinetic models used were zero order 
(%  unreleased  drug  vs  time),  first  order  (log  cumulative 
percentage of drug remaining vs time), Higuchi’s (cumulative 
percentage  of  drug  released  vs  square  root  of  time)  and 
Korsmeyer  (log  cumulative  percentage  of  drug released  vs 
log time) equation. 
RESULTS AND DISCUSSIONS 
Compatibility  studies  were  performed  using  FTIR 
spectrophotometer.  The  IR  spectrum  of  pure  drug  and 
physical  mixture  of  drug  and  polymer  were  studied  by 
making  a  KBr  disc. The  characteristic absorption  peaks  of 
Domperidone  were  obtained  at  different  wave  numbers  in 
different samples. 
The peaks obtained in the spectra of each physical mixture 
correlates  with  the  peaks  of  drug  spectrum. The  FT-IR  of 
pure drug was characterized by N-H stretching at 3126 cm
–1 
and C=O stretching at 1717 cm
-1, indicating the presence of –
CONH group, asymmetric C-H stretching at 2817 cm
-1, C=C 
at 1623 cm
-1 and N=C stretching at 1489 cm
-1.(Fig. 1) The 
FTIR  spectra  of  fast  dissolving  film  formulation  was 
described by N-H stretching at 3127.26cm
-1, Asymmetric C-
H stretching at 2936.66 cm
-1, N=C stretching at 1488.87 cm
-1 
(Fig. 2). All these peaks clearly indicate that they are closely 
similar to the peaks of pure drug. This indicates that the drug 
is compatible with the formulation components.  
The  DSC  thermogram  of  domperidone  exhibited  an 
endothermic peak at 245.54
0C corresponding to its melting 
point.  The  DSC  thermograms  of  domperidone  with  other 
excepitents does not show profound shift in peaks (245.54
0C) 
which indicates compatibility. The DSC thermogram of the 
individual drug and final formulation show in Fig. 3 and Fig. 
4. 
In  order  to  study  the  possibility  of  any  drug  polymer 
interaction, UV spectrum of the various drug loaded inclusion 
complexes were carried out in phosphate buffer pH 6.8 and 
20%  PG.  The  spectrum  indicated  that  there  was  no 
interference or shifting of λmax of domperidone which reflects 
no  drug polymer  interaction.  Drug  content  of  all  inclusion 
complexes  were  in  the  range  of  95.14%  -  97.54%.  This 
indicates the proper loading of drug in inclusion complexes 
and effectiveness of kneading method.
27 The drug content of 
inclusion complexes are as shown in (Table 3). 
It was evident at a glance that all system with CDs exhibited 
better  dissolution  properties  than  pure  drug  alone. 
Statistically  significant  differences  in  term  of  dissolution 
were  found  in  all  the  domperidone-  β-CD  inclusions.  The 
increased  dissolution rate  (physical  mixture)  is  attributable 
both to improvement in drug wettability and to formation of 
readily  soluble  complexes  in  dissolution  medium.  Further 
improvement obtained with kneading could be explained by 
the more intimate contact between drug and carrier and the 
decrease of drug crystallinity, as well as a phenomenon of at 
least  partial  drug  inclusion  complexation.  The  best 
performance of these product seemed to confirm that drug 
inclusion  complexation  occurred  substantially  only  in  such 
systems,  thus  allowing  to  obtain  the  highest  dissolution 
improvement.
27,28  Dissolution  data  of  inclusion  complexes 
also indicated that there was an increase in dissolution (54-
98%  w/v)  as  compared  to  pure  drug  (42%  w/v),  and 
maximum  increase  was  observed  in  case  of  inclusion 
complexes I2 containing 1:1 drug to β-CD ratio (Fig. 5). So, 
1:1 drug to β-CD ratio was selected for further studies. 
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Preliminary Studies 
Preliminary  studies  were  carried  out  to  select  a  suitable 
polymer system and to decide on a good polymer plasticizer 
system, capable of producing films of desirable mechanical 
property  and  disintegration time.  The  film  casting  solution 
was prepared as per solvent casting method. 
The  films  prepared  from  different  combination  of  polymer 
like,  HPMC  E3,  HPMC  E5  and  PVA  in  different 
concentration (B1 to B12) were shown good physical property 
characteristic and inclusion complex loading capacity. From 
all the films, films having HPMC E3 (3%) and HPMC E5 
(4%)  (B10) were shown most desired properties and lower 
disintegration time (31.67±3.06 sec) than other films (Table 
4). As a result an attempt was made to prepare films using 
combination of HPMC E3 (3%) and HPMC E5 (4%) for the 
further studies. 
Experimental Design 
3
2  Factorial  design has  often  been  applied  to  optimize  the 
formulation  variables  with  basic  requirement  of 
understanding  interaction  of  independent  variables. 
Preliminary investigations of the process parameters revealed 
that  factors  like  concentration  of  HPMC  E3  (X1)  and 
concentration  of  HPMC  E5  (X2)  showed  significant 
influence  on  disintegration  time  (R1),  amount  of  drug 
dissolve in 30 min (CPR Q30; R2) and tensile strength (R3) of 
drug loaded fast dissolving film. Hence, they  were utilized 
for  further  systematic  studies.  For  all  9  batches,  both  the 
selected  dependent  variables  (X1  and  X2)  showed  a  wide 
variation in disintegration time, amount of drug release in 30 
min and tensile  strength. The  data  clearly  indicated  strong 
influence of X1 and X2 on selected responses (R1, R2 and 
R3).  The  polynomial  equations  can  be  used  to  draw 
conclusions after considering magnitude of coefficients and 
mathematical  sign  it  conveys  either  positive  or  negative 
(Table  5).  Results  for  experimental  design  batches  and  its 
ANOVA were shown in table 10 and figure 6, 7 & 8. 
Effect of design factors on Disintegration time 
The ANOVA results, contour plot and 3D surface plot for the 
disintegration time (Figure 6) showed the strong effect of the 
two factors (concentration of HPMC E3 and concentration of 
HPMC  E5.  Polynomial  equation  of  the  disintegration  time 
was  indicated  that  the  both  polymer  concentration  have 
positive  effect  on  the  disintegration  time.  In  vitro 
disintegration time of the films was found to increase with 
increase in the amount of the polymer. It was observed that in 
vitro disintegration time varies from 27 to 79 sec for all the 
formulations. In vitro disintegration time of FDF containing 
HPMC E-3 and HPMC E-5 as polymer was affected by the 
thickness  of  the  film.
  In  vitro  disintegration  time  of  the 
formulation  F9  was  maximum  than  other  formulations. 
Maximum concentration of polymers in F9 may be the reason 
for maximum disintegration. 
Effect of design factors on CPR Q30 
The ANOVA results, contour plot and 3d surface plot for the 
amount  of  drug  released  in  30  min  (CPR  Q30;  Figure  7) 
showed the strong effect of the two factors concentration of 
HPMC  E3  and  concentration  of  HPMC  E5.  Polynomial 
equation of the CPR Q30 was indicated that the both polymer 
concentration have positive effect on the CPR Q30. CPR Q30 
of  the  films  were  found  to  decrease  with  increase  in  the 
amount of the polymer. It was observed that CPR Q30 varies 
from 78.42 to 95.90 for all the formulations. CPR Q30 of the 
formulation  F4  was  maximum  than  other  formulations. 
Minimum  CPR  Q30  was  observed  in  F9.  Maximum 
concentration  of  polymers  in  F9  may  be  the  reason  for 
Minimum CPR Q30. 
Effect of design factors on Tensile strength 
The ANOVA results, contour plot and 3D surface plot for the 
tensile strength (Figure 8) showed the strong effect of the two 
factors  (concentration  of  HPMC  E3  and  concentration  of 
HPMC E5. Polynomial equation of the tensile strength was 
indicated that the both polymer concentration have positive 
effect on tensile strength. Tensile strength of the films was 
found to increase with increase in the amount of the polymer. 
It was observed that tensile strength varies from 1.231±0.145 
to 3.093±0.177 for all the formulations. Tensile strength of 
the formulation F9 was maximum than other formulations. 
Maximum concentration of polymers in F9 may be the reason 
for  maximum  disintegration.  Tensile  strength  of  optimized 
formulation F4 was found 2.180±0.065. 
Evaluation parameter of film formulations 
Thickness 
The  thicknesses  of  formulated  films  were  found  to  be  in 
range  of  0.33±0.03 to0.41±0.06  mm.  The  mean  values  are 
tabulated  in  Table  6.  The  values  indicating  that  as  the 
concentration of polymer increases thickness was gradually 
increased. The values are almost uniform in all formulations. 
Obtained  results has  shown  that  increase  in  film  thickness 
decreases tensile strength while increases % elongation.
29 
Weight variation test 
The  percentage  weight  variation  for  all  the  formulation  is 
tabulated in Table 6. All the films passed weight variation 
test as the % weight variation was within the pharmacopoeial 
limits  of  ±7.5%.  It  was  found  to  be  in  range  of 
121.66±3.51to151.34±6.42 mg. The weight of all the films 
was found to be uniform. 
Drug content  
The drug content and content uniformity test was performed 
to  ensure  uniform  and  accurate  distribution  of  drug.  The 
content  uniformity  was  performed  for  all  the  nine 
formulations and results are tabulated in Table 6. Three trials 
from each formulation were analyzed spectrophotometrically. 
The  mean  value  and  standard  deviation  of  all  the 
formulations were calculated. The results indicated that in all 
the  formulations  the  drug  content  was  uniform.  The 
cumulative percentage drug released by each film to the in 
vitro release studies was based on the mean content of the 
drug  present  in  the  respective  film.  The  ranges  of  drug 
content  in  all  the  formulations  were  89.375±0.962  to 
104.279±0.962. 
Surface pH 
The surface pH of the films was ranging from 6.65±0.015to 
6.94±0.080 as shown in table 6. Since the surface pH of the 
films was found to be around the neutral pH, there will not be 
any kind of irritation to the mucosal lining of the oral cavity. 
The standard deviation values calculated for all the films are 
very low which conclude that the surface pH of all the films 
was uniform and within the range. 
% Elongation 
Percent  elongation  is  mainly  based  on  tensile  strength  of 
films. The nature of polymers affects tensile strength and % 
elongation.  The  percentage  elongation  of  all  the  batches 
ranges  from  5-23%  and  percentage  elongation  of  all  films 
was given in Table 7. It increased upon increasing the amount 
of  polymer  as  shown  by  the  formulations.  Formulation  F9 
had highest percentage elongation.  
Folding endurance 
Folding endurance measures the ability of patch to withstand 
rupture, higher the folding endurance lower will be chances Basu B et al. IRJP 2012, 3 (9)                                                                                                    
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of film to rupture easily. The folding endurance of the films 
was  determined  by  repeatedly  folding  a  small  strip  of  the 
films at the same place till it broke and the average folding 
endurance  of  all  films  was  given  in  Table  7.  Folding 
endurance  of  all  the  batches  ranges  from  38.67±1.53  to 
54.33±2.08. 
Increase  in  concentration  of  polymer  increases  folding 
endurance of films but after specific concentration increase in 
concentration of polymer decreases folding endurance. This 
was due to film thickness. More the thickness of lower will 
be  folding  endurance.  F5  formulation  showed  high  folding 
endurance 54.33±2.08. 
Moisture content 
Moisture  loss  is  defined  as  the  quantity  of  moisture 
transmitted  through  unit  area  of  film  in  unit  time.  The 
moisture  content  study  gives  an  idea  about  films  stability 
nature and ability of films to withstand its physicochemical 
properties under normal conditions. It also gives idea about 
hydrophilicity of film formulations.
29 The obtained results are 
tabulated in Table 7. The obtained values are almost uniform 
and  ranges  from  1.37  ±  0.48%  to  3.13  ±  0.53%.  F9 
formulation showed high % moisture content while F1 and 
F2  formulations  showed  low  %  moisture  content.  Higher 
concentration of polymers in F9 may be the reason for higher 
percentage of moisture content. 
In vitro dissolution study 
In vitro release studies of Domperidone patches were carried 
out  in  phosphate  buffer  (pH  6.8).  Cumulative  drug release 
was calculated on the basis of drug content of Domperidone 
present in the respective film. The results obtained in the in 
vitro drug release for the formulations F1 to F9 is tabulated in 
Table  8.  Rapid  drug  dissolution  was  observed  in  F1,  F4, 
which release 92.43, 95.90 %, respectively, at end of 30 min. 
F4  formulation  shows  highest  percent  of  drug  release 
(95.90%) than other formulations and drug release 75.26% 
after 15 min.  
Slow drug dissolution was observed in F6, F9 with release 
81.34%,  78.42  respectively  at  end  of  30  min,  the 
concentration of the polymer increased, and the drug release 
was found to be decreased. This might be due to the increase 
concentration  of  polymer,  results  in  formation  of 
strongmatrix layer caused by more intimate contact between 
the  particles  of  HPMC  results  in  decreased  in  mobility  of 
drug particles in swollen matrices, which leads to decrease in 
drug release.
30,31 From all the evaluation parameters, it has 
been seen that F4 formulation fulfill all the characteristics of 
fast dissolving films, so F4 formulation was selected as best 
formulation.  
In-vitro drug permeation 
From in-vitro drug permeation study, it was found that the 
formulation F4 showed better drug permeation of 66.47% in 
30 min and 80.38% in 45 min. The percentage amount of 
drug permeated was plotted against time to obtain permeation 
profile  as  shown  in  Figure  10.  It  was  observed  that 
domperidone was easily permeated across membrane due to 
BCS class II drug and shown the flux 65.15 µg/h/cm
2. So, the 
result of in- vitro study showed that the domperidone from 
fast  dissolving  film  formulation  was  easily  solubilized  and 
absorbed  from  pregastric  route,  mouth,  pharynx  and 
esophagus.
2,20,32 
Viscosity 
The viscosity of the optimized formulation F4 and marketed 
syrup  formulation  was  measured  using  Brookfield  digital 
viscometer.  Viscosity  of  optimized  F4  formulation  was 
measured   using spindle No: 62 at 65 rpm having torque 99.4 
at 36.8
0c temperature viscosity of film solution was found to 
be  1056  cps.  Viscosity  of  marketed  formulation  was 
measured   using spindle No: 62 at 55 rpm having torque 98.9 
at 36.6
0c temperature viscosity of marketed formulation was 
found  to  be  522  cps.  Viscosity  of  F4  formulation  was 
sufficient to absorb from pregastric route.
33,34 Increasing the 
concentration of a dissolved or dispersed substance generally 
gives  rise  to  increasing  viscosity,  and  also  as  molecular 
weight of a solute increases viscosity increases. 
Stability Studies 
The  optimized  formulations  F4  was  evaluated  for  stability 
studies which were stored at 40
0C at 75% RH tested for 3 
month and were analyzed for their tensile strength, surface 
pH, In vitro disintegration time, drug content, in vitro drug 
release 1 month interval. In vitro drug release show in Figure 
11. The residual drug contents of formulations were found to 
be within the permissible limits and the results were shown in 
the Table 9. There was no significance difference seen in the 
observable parameter. 
Pharmacokinetic study of prepared fast dissolving films 
Data obtained from dissolution studies were fitted to various 
kinetic equations. The kinetic models used were zero order 
(%  unreleased  drug  vs  time),  first  order  (log  cumulative 
percentage of drug remaining vs time), Higuchi’s (cumulative 
percentage  of  drug  released  vs  square  root  of  time)  and 
Korsmeyer  (log  cumulative  percentage  of  drug released  vs 
log time) equation.
 
The  data  of  average  values  were  processed  as  per  Hixon–
Crowell cube root law and are given in the Table 12 and the 
Figure 14. The data of average values were processed as per 
Higuchi’s equation and are represented in the Figures 15. The 
data  of  average  values  were  processed  as  per  Korsmeyer-
Peppas  model  and  are  represented  in  the  Figures  16.  The 
linearity of data for all the models was identified from the 
Figures.  The  equations  were  generated  through  statistical 
procedures and reported in the Table 11 and 12. 
The release data of Domperidone from all the patches were 
given in Figure 9. A perusal to Figure 9 indicated that the 
drug release was highest in F4. Data of the in vitro release 
were fit into different equations and kinetic models to explain 
the  release  kinetics  of  domperidone  from  these  films.  The 
release kinetics of domperidone followed first order from all 
the  films  F1  to  F9.  The  better  fit  (highest  R
2  values)  was 
observed  in  case  of  Higuchi’s  model  than  Hixon–Crowel 
model in all the films. Hence mechanism of drug release from 
the  domperidone  patches  F1  to  F9  followed  are  diffusion 
controlled. Application of Hixon – Crowell cube root law, the 
equation (M0
1/3 – M
1/3) = kt, provides information about the 
release  mechanism,  namely  dissolution  rate  limited. 
Application  of  Higuchi’s  equation  (M  =  K  t
1/2)  provides 
information about the release mechanism, namely diffusion 
rate  limited.  Korsmeyer-Peppasmodel  indicates  that release 
mechanism  is  not  well  known  or  more  than  one  type  of 
release phenomena could be involved. The ‘n’ value could be 
used to characterize different release mechanisms. 
According  to  Korsmeyer-Peppas  model  a  value  of  slope 
between  0.5  and  1indicates  an  anomalous  behavior  (Non-
Fickian).  So,  it  indicates  that  release  mechanism  from  the 
films  F1  to  F8  follows  non-Fickian  diffusion  (anomalous 
behaviour). However, film F9 follows case II transport. 
CONCLUSION 
Inclusion  complex  of  Domperidone  with  β-CD  showed 
improve dissolution behavior pure drug which was prepared 
by kneading method. Among all complexes prepared with β-
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of Domperidone was prepared by the solvent casting method 
showed  acceptable  mechanical  properties  and  satisfactory 
drug release. The multiple regression analysis of the results 
led to the equations that describe adequately the influence of 
the selected variables concentration of  HPMC  E-3  LV  and 
HPMC E-5 LV on the responses under study. Batch F4 was 
found to be optimized batch which contain 2% w/v of HPMC 
E-3 LV, 4% of HPMC E-5 LV and 1% w/v PVA. It was 
observed from the results that, F4 formulations which have 
35.33  seconds  disintegration  time  and  showed  maximum 
dissolution rate compare to other formulations about 95.90% 
of drug release in 30 min In vitro permeation 80.38% in 45 
min. In vitro release and In vitro permeation evaluation of 
film  confirmed  their  as  an  innovative  dosage  from  to 
improve delivery of Domperidone. 
 
Table 1: AMOUNT OF VARIABLES IN A 3
2 FACTORIAL DESIGN 
Coded values  Actual values 
X1:HPMC E3  X2:HPMC E5 
-1  2%  3.00% 
0  3%  4.00% 
1  4%  5.00% 
 
Table 2: 3
2 FACTORIAL DESIGN 
Formulations  X1  X2 
F1  -1  -1 
F2  0  -1 
F3  +1  -1 
F4  -1  0 
F5  0  0 
F6  +1  0 
F7  -1  +1 
F8  0  +1 
F9  +1  +1 
 
Table 3: OPTIMIZATION OF β-CYCLODEXTRIN 
Formulation  Drug + β-CD  Drug content (%)*  CPR at 90 min 
I1  1:0.5  95.30±1.47  81% 
I2  1:1  97.54±0.83  98% 
I3  1:1.5  96.41±1.21  54% 
I4  1:2  95.14±1.27  65% 
Drug  -  -  42% 
*All results are shown in mean± S.D. (n=3) 
 
Table 4: Characteristics of Domperidone inclusion complex loaded film prepared  using different polymer 
Batch
a  Polymer  Concentration 
(%w/v) 
Remark  Disintegration time
b (sec) 
B1  HPMC E3  3  Poor  -- 
B2  HPMC E3  4  Poor  -- 
B3  HPMC E3  5  Poor  -- 
B4  HPMC E5  3  Poor   
B5  HPMC E5  4  Poor  -- 
B6  HPMC E5  5  Poor  -- 
B7  HPMCE3+Maltodextrin  3+ 3  Sticky  -- 
B8  HPMCE3+Maltodextrin  3+ 5  Sticky  -- 
B9  HPMC E3+HPMC E5  3+ 3  Average  28.67±2.08 
B10  HPMC E3+ HPMC E5  3+ 4  Good  31.67±3.06 
B11  HPMC E3+ HPMC E5  3+ 5  Good  50.33±0.58 
B12  HPMC E3+ PVA  3+ 2  Average  44.34±1.52 
aEach formulation contains 0.3 ml PG and 0.3 ml glycerin.
 
bAll results are shown in mean ± S.D. (n=3) 
 
Table 5: Design Summary 
  R1  R2  R3 
Formulation Code  Disintegration Time* (sec)  Q30  Tensile strength* (N/cm2) 
F1  27.33±3.51  92.43  1.231±0.145 
F2  37.33±3.06  90.64  1.584±0.172 
F3  53.67±2.52  84.86  2.057±0.058 
F4  35.33±2.08  95.90  2.180±0.065 
F5  51.66±2.51  89.06  2.381±0.042 
F6  59.33±1.53  81.34  2.875±0.058 
F7  50.00±2.65  90.90  2.512±0.316 
F8  64.33±3.51  83.22  2.639±0.307 
F9  79.00±3.61  78.42  3.093±0.177 
*All results are shown in mean± S.D. (n=3); R1: Response 1, R2: Response 2, R3: Response 3. 
 
Table 6: Characterization of fast dissolving film 
Formulations 
 
Weight variation* (mg)  Thickness* (mm)  Surface* pH  Drug content* 
F1  121.66±3.51  0.33±0.03  6.65±0.015  89.375±0.962 
F2  124.33±2.08  0.36±0.05  6.79±0.094  97.067±1.272 
F3  140.66±7.57  0.43±0.08  6.82±0.065  93.221±1.442 
F4  135.66±4.72  0.41±0.10  6.84±0.045  97.548±0.962 
F5  146.33±5.13  0.47±0.08  6.70±0.032  95.625±0.481 
F6  154.00±6.24  0.46±0.05  6.92±0.055  100.913±1.923 
F7  143.33±5.03  0.41±0.06  6.83±0.051  102.837±2.203 
F8  151.34±6.42  0.44±0.06  6.94±0.080  104.279±0.962 
F9  159.33±5.03  0.51±0.08  6.72±0.037  90.817±1.733 
*All results are shown in mean± S.D. (n=3) 
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Table 7: Characterization of fast dissolving film 
Formulation code  Folding endurance*  % Elongation*  % Moisture content*  CPR (%)* 
F1  41.00±2.65  5.33±1.15  1.37±0.48  99.42 
F2  49.67±1.53  8.67±2.31  1.88±0.50  99.55 
F3  42.33±2.52  12.67±2.31  2.37±0.37  97.73 
F4  50.67±3.06  10.67±3.06  2.21±0.08  99.68 
F5  54.33±2.08  16.00±2.00  2.50±0.34  98.72 
F6  45.33±2.31  19.33±4.16  2.58±0.55  96.96 
F7  46.33±1.15  17.33±3.06  2.56±0.43  98.07 
F8  41.67±2.08  20.67±4.16  2.88±0.51  96.36 
F9  38.67±1.53  22.67±5.03  3.13±0.53  97.56 
*All results are shown in mean± S.D. (n=3) 
 
Table 8: Dissolution of all formulations 
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Table 9: Results of accelerated stability studies 
Evaluation parameters  Time period for sampling 
  Intial  After 1 month  After 3 months 
pH  6.84±0.045  6.92±0.092  6.95±0.067 
Disintigration time (min)  35.33±2.08  36.15±3.24  36.54±2.46 
Tensile strength  2.180±0.065  2.128±0.112  2.097±0.089 
Drug content (%)  97.548±0.962  96.896±1.216  96.342±1.672 
CPR30  95.90±2.12  94.09±0.79  91.73±3.04 
All results are shown in mean± S.D. (n=3) 
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Table 10: Regression analysis of model 
Coefficient  Disintegration time  CPR30  Tensile strength 
FM  RM  FM  RM  FM 
β0  48.993  50.887  88.988  87.419  2.396 
β1  13.223  13.223  -5.768  -5.768  0.350 
β2  12.500  12.500  -2.565  -2.565  0.562 
β11  -0.330    -0.332    0.123 
β22  3.170    -2.022    -0.293 
β12  0.665    -1.228    -0.061 
 
Table 11: Comparison of order of in vitro release of domperidone from all the formulations 
Formulation  Zero Order  First Order 
F1  y = -1.664x + 76.02 
R² = 0.750 
y = -0.036x + 2.014 
R² = 0.996 
F2  y = -1.643x + 76.05 
R² = 0.799 
y = -0.042x + 2.066 
R² = 0.960 
F3  y = -1.669x + 81.68 
R² = 0.840 
y = -0.027x + 2.009 
R² = 0.998 
F4  y = -1.636x + 72.88 
R² = 0.733 
y = -0.046x + 2.036 
R² = 0.974 
F5  y = -1.560x + 74.27 
R² = 0.796 
y = -0.030x + 1.983 
R² = 0.998 
F6  y = -1.669x + 83.42 
R² = 0.857 
y = -0.025x + 2.012 
R² = 0.998 
F7  y = -1.767x + 85.14 
R² = 0.851 
y = -0.030x + 2.040 
R² = 0.986 
F8  y = -1.657x + 82.00 
R² = 0.825 
y = -0.024x + 1.991 
R² = 0.995 
F9  y = -1.726x + 87.95 
R² = 0.892 
y = -0.026x + 2.049 
R² = 0.990 
     
 
Table 12: Regression equations of in vitro release of Domperidone from all the formulations 
Formulations  Hixon - Crowell  Higuchi  KorsmeyerPeppas 
F1  y = 0.065x + 0.283 
R² = 0.951 
y = 15.08x + 0.156 
R² = 0.923 
y = 0.920x + 0.648 
R² = 0.823 
F2  y = 0.069x + 0.229 
R² = 0.965 
y = 14.68x + 1.163 
R² = 0.955 
y = 0.844x + 0.742 
R² = 0.774 
F3  y = 0.057x + 0.179 
R² = 0.972 
y = 14.57x - 3.694 
R² = 0.960 
y = 0.867x + 0.661 
R² = 0.821 
F4  y = 0.072x + 0.327 
R² = 0.937 
y = 14.96x + 3.247 
R² = 0.918 
y = 0.859x + 0.748 
R² = 0.771 
F5  y = 0.059x + 0.314 
R² = 0.968 
y = 13.98x + 3.933 
R² = 0.958 
y = 0.791x + 0.812 
R² = 0.722 
F6  y = 0.055x + 0.150 
R² = 0.979 
y = 14.49x - 5.148 
R² = 0.969 
y = 0.906x + 0.595 
R² = 0.857 
F7  y = 0.062x + 0.102 
R² = 0.961 
y = 15.28x - 7.939 
R² = 0.955 
y = 0.973x + 0.503 
R² = 0.897 
F8  y = 0.054x + 0.194 
R² = 0.963 
y = 14.58x - 4.240 
R² = 0.958 
y = 0.963x + 0.536 
R² = 0.873 
F9  y = 0.056x + 0.051 
R² = 0.993 
y = 14.72x - 9.509 
R² = 0.973 
y = 1.105x + 0.301 
R² = 0.905 
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Fig. 2: FTIR of fast dissolving film formulation 
 
Fig 3: DSC of Pure drug 
 
Fig. 4: DSC of optimized fast dissolving film Basu B et al. IRJP 2012, 3 (9)                                                                                                    
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Fig. 5: In vitro release of domperidone in phosphate buffer (pH 6.8) from inclusion complex. 
 
 
Figure 6: Contour plot and 3D Surface Plot of disintegration time (sec) against amount of HPMC E3 (%w/v) and amount of HPMC E5 (%w/v) 
 
 
 
 
Figure 7: Contour plot and 3D Surface Plot of CPR30 (%) against amount of HPMC E3 (%w/v) and amount of HPMC E5 (%w/v) 
 
 
 
 
 
 
 
 
 
Figure 8: Contour plot and 3D Surface Plot of tensile strength (N/cm
2) against amount of HPMC E3 (%w/v) and amount of HPMC E5 (%w/v) 
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Figure 9: In vitro release of domperidone in phosphate buffer (pH 6.8 +20 % 
v/v PG) from film formulation. 
 
 
Figure 10: In vitro permeation of Domperidone from film formulation. 
 
 
Figure 11: In vitro drug release of Domperidone from optimized formulation 
after and before stability study 
 
 
Figure 12: In vitro release of domperidone from F4 in phosphate buffer (pH 
6.8) formulation. Zero order release. 
 
 
Figure 13: In vitro release of domperidone from F4 in phosphate buffer (pH 
6.8). First order release. 
 
 
Figure 14: In vitro release of Domperidone from F4 in phosphate buffer (pH 
6.8) formulation. Hixon Crowell. 
 
 
Figure 15: In vitro release of Domperidone from F4 in phosphate buffer (pH 
6.8) formulation. Higuchi’s release model. 
 
 
 
Figure 16: In vitro release of Domperidone from F4 in phosphate buffer (pH 
6.8) formulation. Korsmeyer-Peppas model. 
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